Christie has announced the launch of its CounterAct line of commercial UV disinfection products with patented Care222 far-UVC light technology. Developed by Christie’s parent company, Ushio Inc – based on technology licensed from Columbia University – Christie CounterAct introduces an added layer of defence against pathogens in indoor venues, even when guests and staff are present (when used in accordance with specified parameters).
The Care222 far-UVC, mercury-free excimer lamp – highlighted in FORTUNE magazine’s annual Change the World list in 2020 – includes a proprietary short pass filter that prevents the emission of longer wavelengths of UV light (230nm and higher) that are capable of penetrating human skin and eyes, an especially important feature that other 222nm and far-UVC products do not have.
Far-UVC 222nm light is the only UV technology that can used while people are present shown to continuously and significantly reduce pathogens, like coronaviruses. Mass production of the new Christie CounterAct fixture begins in January 2021.
“People are essential to the entertainment industry, and their level of comfort in public venues is paramount to the industry’s success,” said Zoran Veselic, president and COO at Christie. “We are very proud to be able to offer this product with Ushio’s Care222 technology to our partners, and we are excited about the possibilities the technology will have in bringing customers back to the places they love, such as movie theatres and theme parks.”
